MedTrace Logo

Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections

NCT00156377 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2010-05-25

No results posted yet for this study

Summary

In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent Staphylococcus aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections.

Conditions

  • Cross Infection
  • Staphylococcal Infections

Interventions

DRUG

Mupirocin

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Christof von Eiff, MD · University Hospital of Muenster, Institute of Medical Microbiology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156377 on ClinicalTrials.gov